Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis Who Have Type 2 Diabetes (T2DM) or Pre-Diabetes

NCT05623189 is registered in ClinicalTrials.gov with HighTide Therapeutics (Hong Kong) Limited as lead sponsor.

NCT NCT05623189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05623189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis Who Have Type 2 Diabetes (T2DM) or Pre-Diabetes
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Phase
Phase 2
Overall status
Completed
Start date
December 27, 2022
Completion date
March 31, 2025
Enrollment
218 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash), type 2 diabetes